Characterization of rare transforming KRAS mutations in sporadic colorectal cancer

KRAS mutational status has been shown to be a predictive biomarker of resistance to anti-EGFR monoclonal antibody (mAb) therapy in patients with metastatic colorectal cancer. We report the spectrum of KRAS mutation in 1506 patients with colorectal cancer and the identification and characterization o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Joanna HM, Lung, Raymond WM, Sin, Frankie MC, Law, Peggy PY, Kang, Wei, Chan, Anthony WH, Ma, Brigette BY, Mak, Tony WC, Ng, Simon SM, To, Ka Fai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049792/
https://www.ncbi.nlm.nih.gov/pubmed/24642870
http://dx.doi.org/10.4161/cbt.28550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049792/
https://www.ncbi.nlm.nih.gov/pubmed/24642870
http://dx.doi.org/10.4161/cbt.28550

Ejemplares similares